New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
October 24, 2012
10:01 EDTQCOR, ININ, MYGN, FB, ACC, GLNG, ST, MCP, DLTR, WHR, REE, IBKC, BACOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: American Campus (ACC) upgraded to Buy from Neutral at UBS... Bank of America (BAC) upgraded to Overweight from Neutral at Atlantic Equities... Dollar Tree (DLTR) upgraded to Conviction Buy from Neutral at Goldman... Eagle Bancorp (EGBN) upgraded to Outperform from Market Perform at FBR Capital... Facebook (FB) upgraded to Buy from Neutral at BofA/Merrill... Facebook (FB) upgraded to Buy from Neutral at Citigroup... IBERIABANK (IBKC) upgraded to Outperform from Market Perform at Keefe Bruyette... Molycorp (MCP) upgraded to Buy from Hold at Dahlman Rose... Myriad Genetics (MYGN) upgraded to Buy from Neutral at BofA/Merrill... Rare Element (REE) upgraded to Hold from Sell at Dahlman Rose... Sensata (ST) upgraded to Buy from Neutral at Janney Capital... Whirlpool (WHR) upgraded to Buy from Sell at Goldman... Interactive Intelligence (ININ) upgraded to Outperform at Northland... Golar LNG (GLNG) upgraded to Outperform from Market Perform at FBR Capital... Whirlpool (WHR) upgraded to Strong Buy from Outperform at Raymond James... Questcor (QCOR) upgraded to Buy from neutral at Ladenburg.
News For ACC;BAC;DLTR;FB;IBKC;MCP;MYGN;REE;ST;ININ;WHR;GLNG;QCOR From The Last 14 Days
Check below for free stories on ACC;BAC;DLTR;FB;IBKC;MCP;MYGN;REE;ST;ININ;WHR;GLNG;QCOR the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | all recent news | >>
April 8, 2014
07:20 EDTQCORMallinckrodt shares pressured on lingering Acthar concerns, says Jefferies
Jefferies says shares of Mallinckrodt (MNK) sold off yesterday despite "significant accretion potential" from the Questcor (QCOR) acquisition due to lingering Acthar concerns relating to generic competition and the ongoing U.S. Attorney's investigation. The firm says its accretion math suggests $3 in earnings per share by FY15, which it feels justifies a $75-$85 share range for Mallinckrodt. It keeps a Buy rating on the stock with a $77 price target.
07:08 EDTQCORDrug deals increase to new high, Bloomberg says
M&A activity in the specialty pharmaceuticals industry has reached a new high after Mallinckrodt (MNK) recently bought Questcor (QCOR) for $5.6B, reported Bloomberg. Drugmakers from Actavis (ACT) to Valeant (VRX) are widening their suites of drugs through takeovers that immediately increased earnings with the help of lower corporate tax rates in countries such as Ireland. Reference Link
06:40 EDTQCORMallinckrodt upgraded to Outperform from Market Perform at BMO Capital
Subscribe for More Information
05:31 EDTQCORQuestcor downgraded to Hold from Buy at Jefferies
Jefferies downgraded Questcor (QCOR) to Hold with an $86 price target following the company's merger agreement with Mallinckrodt (MNK).
April 7, 2014
19:57 EDTBACFederal Reserve announces extension on some CLOs
The Federal Reserve Board announced that it intends to exercise its authority to give banking entities two additional one-year extensions to conform their ownership interests in and sponsorship of certain collateralized loan obligations, or CLOs, covered by section 619 of the Dodd-Frank Wall Street Reform and Consumer Protection Act, commonly referred to as the Volcker rule. Section 619 of the Dodd-Frank Act directed the board to adopt rules for the conformance period and the board previously extended the conformance period for all activities and investments by one year to July 21, 2015. To ensure effective compliance, the board intends to grant banking entities two additional one-year extensions, which together would extend until July 21, 2017, to conform their ownership interests in and sponsorship of CLOs to the statute. Publicly traded companies that may be impacted by the announcement include Bank of America (BAC), Citigroup (C), Goldman Sachs (GS), JPMorgan (JPM), Morgan Stanley (MS), U.S. Bancorp (USB) and Wells Fargo (WFC). Reference Link
16:34 EDTMYGNMyriad Genetics submits premarket approval to FDA for BRACAnalysis
Subscribe for More Information
16:28 EDTQCOROn The Fly: Closing Wrap
Subscribe for More Information
12:15 EDTQCOROn The Fly: Midday Wrap
Subscribe for More Information
11:21 EDTQCOROptions with decreasing implied volatility: QCOR MU KMX EPB
11:09 EDTMYGNMyriad Genetics advises prior BRACAnalysis news release be disregarded
Myriad Genetics advised that readers should disregard the news release, "Myriad Genetics Submits Premarket Approval to FDA for BRACAnalysis" issued April 7 by the company over GlobeNewswire.
11:05 EDTQCOR High option volume stocks: EXC QCOR SQQQ GNK PPG
Subscribe for More Information
10:40 EDTQCORShort-seller target Questcor spikes after deal to be bought by Mallinckrodt
Questcor (QCOR) shares are sharply higher this morning after the company agreed to be bought by Mallinckrodt (MNK) in a transaction valued at approximately $5.6B. WHAT'S NEW: Questcor, a biopharmaceutical company whose primary drug, H.P. Acthar Gel, is approved by the FDA for the treatment of 19 indications, will be acquired by Mallinckrodt for about $5.6B, made up of $30.00 per share in cash and 0.897 Mallinckrodt shares for each Questcor share they own. The total consideration equated to approximately $86.10 per Questcor share based on the closing price of Mallinckrodt shares on April 4. After the deal closes, Mallinckrodt shareholders will own approximately 50.5% and former Questcor shareholders will own approximately 49.5% of the combined company's stock. The deal is expected to immediately add to Mallinckrodt's fiscal 2014 adjusted earnings per share and significantly add to fiscal 2015 adjusted EPS. The transaction is targeted to close in the third quarter. On the companies' conference call discussing the merger, Questcor said it believes that its first quarter sales will be "somewhat lower" than the fourth quarter of 2013, but also "substantially higher" than last year's first quarter; the consensus estimate for Q1 revenue is $242.08M. Questcor also said that it sees a "favorable" tax structure and operating cash flow, as well as immediate value for shareholders. Mallinckrodt said sees about a 10% decline in the tax rate with the Questcor deal and believes it will realize immediate tax benefits. Mallinckrodt added that its focus will be on deleveraging in the coming months to allow for strategic acquisitions. WHAT'S NOTABLE: Of the 19 indications approved for Acthar, Questcor currently generates substantially all of its net sales from the following on-label indications: the treatment of proteinuria in the nephrotic syndrome of the idiopathic type, or NS, the treatment of acute exacerbations of multiple sclerosis, or MS, in adults, the treatment of infantile spasms, or IS, in infants and children under two years of age, and the treatment of certain rheumatology related conditions. Questcor has been a frequent target of the short-selling blog Citron Research in the past. As recently as March 14, Citron Research claimed Questcor was "deceiving" the FDA and investors, alleging H.P. Acthar Gel's active ingredient is less than 20% of the label specification. PRICE ACTION: Questcor is trading up $11.48, or 16.91%, to $79.35 in mid-morning trading. Meanwhile, Mallinckrodt is down $1.70, or 2.72%, to $60.82.
10:16 EDTMYGNMyriad Genetics has a conference call hosted by JPMorgan
Subscribe for More Information
10:00 EDTQCORQuestcor rises 21.2%
Subscribe for More Information
09:10 EDTQCOROn The Fly: Pre-market Movers
HIGHER: Questcor (QCOR), up 27% after agreeing to be bought by Mallinckrodt (MNK) for cash, stock valued at $86.10 per Questcor share... Agios Pharmaceuticals (AGIO), up 25% after program shows "promising clinical activity" for advanced blood cancers, shares upgraded at JPMorgan... Vocus (VOCS), up 47% after agreeing to be acquired by GTCR for $446.5M, or $18.00 per share... Pandora (P), up 1.3% following upgrade at Wedbush. LOWER: MannKind (MNKD), down 13% after announcing FDA extension of PDUFA date for Afrezza... American Eagle (AEO), down 2.2% following downgrade at Cowen... Pfizer (PFE), down 2.8% after announcing data for palbociclib in metastatic breast cancer... Mattel (MAT), down 3% following downgrade at BMO Capital... WWE (WWE), down 1.2% after cautious mention in Barron's, company announcing WrestleMania 30 grossed $10.9M.
09:00 EDTQCORQuestcor rises 29.2%
Subscribe for More Information
07:16 EDTQCORMallinckrodt and Questcor hold a joint conference call
Subscribe for More Information
07:08 EDTQCORQuestcor to be bought by Mallinckrodt for cash, stock valued at $86.10 per share
Subscribe for More Information
07:04 EDTQCORQuestcor acquired by Mallinckrodt for $5.6B
Subscribe for More Information
05:48 EDTMYGNMyriad Genetics submits premarket approval to FDA for BRACAnalysis
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | 6 | 7 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use